Table 1 Clinical characteristics of 18,347 esophageal cancer patients without missing data, diagnosed from 2010 to 2018
Without BrM (N = 18,149) | With BrM (N = 198) | P-value | |
|---|---|---|---|
Age (years) | |||
< 65 | 7441 (41.0%) | 112 (56.6%) | < 0.001 |
> =65 | 10,708 (59.0%) | 86 (43.4%) | |
Sex | |||
Male | 14,305 (78.8%) | 174 (87.9%) | 0.003 |
Female | 3844 (21.2%) | 24 (12.1%) | |
Race | |||
White | 15,487 (85.3%) | 178 (89.9%) | < 0.001 |
Black | 1669 (9.2%) | 6 (3.0%) | |
Asian or Pacific Islander | 878 (4.8%) | 9 (4.5%) | |
American Indian/Alaska Native | 115 (0.6%) | 5 (2.5%) | |
Primary site | |||
Upper third | 1401 (7.7%) | 4 (2.0%) | < 0.001 |
Middle third | 3540 (19.5%) | 31 (15.7%) | |
Lower third | 12,450 (68.6%) | 144 (72.7%) | |
Overlapping lesion | 758 (4.2%) | 19 (9.6%) | |
Histology | |||
Esophageal squamous cell carcinoma | 6318 (34.8%) | 35 (17.7%) | < 0.001 |
Esophageal adenocarcinoma | 11,831 (65.2%) | 163 (82.3%) | |
Grade | |||
Grade I | 1197 (6.6%) | 8 (4.0%) | 0.007 |
Grade II | 7886 (43.5%) | 67 (33.8%) | |
Grade III | 8837 (48.7%) | 119 (60.1%) | |
Grade IV | 229 (1.3%) | 4 (2.0%) | |
T stage | |||
T1 | 5226 (28.8%) | 75 (37.9%) | < 0.001 |
T2 | 2438 (13.4%) | 19 (9.6%) | |
T3 | 8217 (45.3%) | 53 (26.8%) | |
T4 | 2268 (12.5%) | 51 (25.8%) | |
N stage | |||
N0 | 7606 (41.9%) | 42 (21.2%) | < 0.001 |
N1 | 7674 (42.3%) | 126 (63.6%) | |
N2 | 2138 (11.8%) | 16 (8.1%) | |
N3 | 731 (4.0%) | 14 (7.1%) | |
Bone metastases | |||
None | 17,213 (94.8%) | 145 (73.2%) | < 0.001 |
Yes | 936 (5.2%) | 53 (26.8%) | |
Liver metastases | |||
None | 16,365 (90.2%) | 134 (67.7%) | < 0.001 |
Yes | 1784 (9.8%) | 64 (32.3%) | |
Lung metastases | |||
None | 17,066 (94.0%) | 140 (70.7%) | < 0.001 |
Yes | 1083 (6.0%) | 58 (29.3%) | |